跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
DELSTRIGO - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
DELSTRIGO
Authorized
STANDARD
DELSTRIGO
Merck Canada Inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
df6c2af0ec90a49a
Company
Merck Canada Inc
Type
Standard
Approval Details
Approval Id
df6c2af0ec90a49a
Drug Approval Canada Name
DELSTRIGO
Product Name
DELSTRIGO
Status
Marketed
Status Date
2018-12-10
Original Market Date
2018-12-10
Din
02482592
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Oral
Schedule
Prescription
Ahfs
08:18.08.20
Atc Original
J05AR24 LAMIVUDINE, TENOFOVIR DISOPROXIL AND DORAVIRINE
Atc Name
j 05 ar 24
Aig Number
0360870001
Company Name
Merck Canada Inc
Company Address
16750 Route Transcanadienne, Kirkland, Quebec, Canada, H9H 4M7
Active Ingredients
DORAVIRINE
100 MG
LAMIVUDINE
300 MG
TENOFOVIR DISOPROXIL FUMARATE
300 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
df6c2af0ec90a49a
Type
Standard
Back to Health Canada Approvals